Skip to content

Market explorer

Screen the results we have checked

Search and filter our published results. This is selected coverage, not a screen of every listed stock.

Read the basis before comparing. Revenue is the company's reported revenue line, not a standardised comparable measure. Excise, acquisitions, exceptional items and different reporting periods can change growth. Missing revenue or growth is not zero. Each result below keeps its filing basis and caveats. No live prices, valuation filters or recommendations.

1 matching results out of 156 published entries. 69 have revenue growth available.

Strides Pharma Science

+17.11% revenue YoY

Q2 FY2027 · Period ended 30 Sep 2026

Basis: Consolidated, unaudited; June includes loss-of-control gain

Reported revenue (₹ crore, except EPS in ₹/share): 1429.73

Read summary and comparison caveats

Strides Pharma Science reported consolidated operating revenue of ₹1,429.73 crore, up 17.11% year on year and 12.99% from June. Owners' profit was ₹130.84 crore, up 2.59% year on year but down 16.62% quarter on quarter. June included a ₹74.21 crore gain on losing control of Pivot Path, including remeasurement of the retained stake; the sequential profit comparison is not a clean operating-growth measure. Basic and diluted EPS were both ₹14.19.

  • Source: consolidated statement on PDF pages 6-7, notes on pages 13-14, and limited-review report on pages 2-3. Original ₹ million amounts are divided by 10 for crore. Percentage changes use original amounts before rounding; EPS changes use reported per-share figures.
  • Year ago is 30 Sep 2025; previous quarter is 30 Jun 2026. Owners' PAT is ₹1,308.36 million versus ₹1,275.34 million and ₹1,569.14 million. Group PAT is ₹1,341.18 million versus ₹1,315.24 million and ₹1,654.93 million; non-controlling profit is ₹32.82 million versus ₹39.90 million and ₹85.79 million. These bases are not mixed.
  • June exceptional items included a ₹742.07 million gain from dilution of Pivot Path to 19.95%, loss of control and remeasurement of the retained investment. June also had ₹110.10 million product-recall/settlement expense, leaving net exceptional gain ₹631.97 million. Current exceptional items are ₹17.04 million expense, versus ₹87.72 million expense a year ago. No adjusted PAT is invented by subtracting pre-tax gains from post-tax profit.
  • Current product-recall/settlement expense comprises ₹13.52 million for ranitidine/losartan withdrawal, settlements and related legal fees and ₹3.52 million for testosterone recall/related expenses. The notes describe ongoing litigation and legal complaints under evaluation; a charge is not evidence that all liabilities are settled.
  • Current pre-exceptional PBT is ₹1,512.41 million. After ₹17.04 million exceptional expense and ₹8.99 million share of associate/JV profit, PBT is ₹1,504.36 million. Current tax ₹216.79 million less deferred-tax credit ₹53.61 million gives tax ₹163.18 million and group PAT ₹1,341.18 million. Deferred tax was a credit ₹11.46 million a year ago and expense ₹51.17 million in June; no tax-normalised profit is estimated.
  • Current group OCI ₹391.59 million and total comprehensive income ₹1,732.77 million are not PAT. EPS is not annualised. The separate standalone PAT ₹92.63 million is not added to consolidated profit; the standalone June exceptional gain ₹764.01 million differs from the consolidated ₹742.07 million gain.
  • The limited-review report includes two subsidiaries reviewed by other auditors and 25 subsidiaries not reviewed, plus four associates and a joint venture with unreviewed interim information. Unreviewed subsidiaries have quarter revenue ₹1,668 million and loss ₹244 million before consolidation adjustments; management describes this information as immaterial to the group. The review conclusion is unmodified. A limited review is not an audit.
  • Selected original-source coverage, not a complete market list. Duplicate filings, board-meeting notices and newspaper copies are not additional results. Raw RSS notice time carries no timezone suffix.

Checked 29 Oct 2026

Open original filing
Read the complete published results desk